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Bone marrow transplantation was the term origilnally used to describe the collection and translplantation of hematopoietic stem cells from the 
bone marrow, but with the recent demonstration that 
the peripheral blood and umbilical cord blood are also 
useful sources of stem cells, hematopoietic stem cell 
transplantation (HSCT) has become the preferred 
generic term. The procedure is usually carried out for 
one of two purposes: (1) to replace an abnormal but 
nonmalignant lymphohematopoietic system with one 
from a normal donor, or (2) to treat malignancy by all
lowing the administration of higher doses of myelosupl
pressive therapy than would otherwise be possible. The 
use of bone marrow transplantation has been steadily 
increasing, both because of its demonstrated effectivel
ness in selected diseases and because of the increasing 
availability of donors. The International Bone Marrow 
Transplant Registry estimates that about 50 000 transl
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since 1991, 2042 first hematopoietic stem cell transplants (hsct) have been performed at the hematology-
oncology and stem cell transplantation research center at tehran university of medical sciences. 
acute myelogenous leukemia (548 patients), thalassemia major (335 patients) and acute lymphoblastic 
leukemia (275 patients) have been the most common transplanted disorders. there were 1418 cases that 
received allogeneic hsct and 624 cases that have received autologous hsct. the numbers of alloge-
neic and autologous hsct have increased, but the allogeneic to autologous ratio has remained con-
stant. the first peripheral blood hematopoietic stem cell transplantation was performed in 1996; since 
then, 1671 have been done. the donor types for 1418 allogeneic first hsct were 1367 (96.4%) human 
leukocyte antigen (hla) matched-identical siblings, 29 (2%) hla-mismatched sibling/other relative, 13 
(0.9%) syngeneic twins, 5 (0.4%) hla-matched other relatives and 4 (0.3%) unrelated.  the first cord 
blood hematopoietic stem cell transplantation was performed in 1998 and since then there have been 
14 patients that have obtained cord blood transplantations. recently, new methods have been used like 
donor lymphocyte infusion (dli) and cellular therapy. there were 111 patients with cellular therapy for 
post-myocardial infarction, cirrhosis, thalassemia major, multiple sclerosis, head of femur necrosis and 
renal cell carcinoma.
plants are performed each year.1, 2
The HematologylOncology and Stem Cell 
Transplantation Research Center at Tehran University 
of Medical Sciences is located in Shariati Hospital. The 
first HSCT was performed by Professor Ghavamzadeh 
and colleagues in 1991, who have continued to carry 
out this treatment for different kinds of cancers and 
hemoglobical disorders. The center is a member of 
the International Blood and Marrow Transplantation 
Registry (IBMTR) and the European of Blood and 
Marrow Transplantation Registry (EBMTR). In asl
sociation with these organizations, the center collects 
data on patients who have undergone transplantation 
and cooperates with these centers in various scientific 
and research fields. This center is a member of Asian 
Pacific Cancer Center (APCC) and also has collabol
rations with blood and cancer associations such as 
the American Society of Hematology (ASH), the 
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International Society of Hematology (ISH), and the 
European School of Medical Oncology (ESMO), the 
American Society of Clinical Oncology (ASCO), and 
other centers. The plans and aims include expansion of 
cytogenetic and molecular biological diagnostic tests, 
establishment of a cord blood bank and development of 
research activities in these fields.3
PATIenTS AnD MeThODS 
Stem cell sources for patients underwent HSCT in the 
HematologylOncology and Stem Cell Transplantation 
Research Center from March 1991 to December 2007 
were bone marrow, peripheral blood, cord blood, coml
bining bone marrow and peripheral blood, and mesl
enchymal origins.   Depending on the condition of the 
patient, we used allogeneic, autologous or syngeneic 
stem cell grafts.4 All patients were treated in completely 
isolated rooms during the peritransplant period. These 
were conventional rooms that were private and HEPAl
filtered with home entertainment appliances to avoid 
depression. Stem cells were obtained and kept at 4ºC 
for 1 to 4 days before reinfusion. The stem cells were 
reinfused without purging.5 The center has a research 
office with a data management section that gathers the 
stem cell transplantation data from stem cell transplanl
tation wards, checking reports for completeness of data 
and identifying missing data, correcting missing fields, 
and entering report forms into the computer database 
program (Software version 3.2.4 that meets the needs of 
HSCT centers) for statistical analysis and preparation 
of statistical reports, finally sending them to CIBMTR. 
The office is also responsible for quality control of the 
data entry processes and training patients and stem cell 
transplantation and data management staff. In Iran, 
which has a population of about 70 million people, 
the incidence of transplantable diseases is estimated at 
about 2 per 100 000 or 1400 patients per year. The cost 
of transplant procedures is borne by insurance compal
nies and the board of trustees.
The number of HSCTs indicates the number of pal
tients treated for the first time with HSCT. The transl
plant rate is defined as the number of HSCTs per 1 mill
lion inhabitants.6 Population data were obtained from 
the Statistical Center of Iran (www.sci.org.ir). Reltransl
plant was defined as an unplanned HSCT for rejecl
tion or relapse after a first HSCT. Donor lymphocyte 
infusion (DLI) is a method for treatment of patients 
with recurrent or persistent malignancy after allogeneic 
HSCT with infusion of additional lymphocytes obl
tained from the original donor, without the cover of iml
munosuppressive agents.7 Cell therapy is a technology 
that relies on replacing diseased or dysfunctional cells 
with healthy, functioning ones.
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Figure 1. Number of first hematopoietic stem cell transplantations from 1991 to 2007.
special communicationiRaN
Hematol Oncol Stem Cell Ther 1(4)     October 2008 hemoncstem.edmgr.com 233
 1991   1992    1993   1994   1995  1996   1997   1998   1999    2000   2001   2002   2003   2004   2005   2006   2007 
Ra
te
 p
er
 m
ill
io
n
6
5
4
3
2
1
0
year of transplantation
Figure 2. Total rate per million of first hematopoietic stem cell transplantations during 
the past 17 years.
Figure 3. Number of allogeneic and autologous hematopoietic stem cell transplantations.
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Figure 5. Number of peripheral blood and bone marrow hematopoietic stem cell transplantations.
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Figure 4. Standardized rate of allogeneic and autologous hematopoietic stem cell 
transplantations in the past 17 years.
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Figure 7. Hematopoietic stem cell 
transplantation number for thalassemia 
patients.
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Figure 6.  Hematopoietic stem cell 
transplantation number by graft type 
for aml patients (upper). Standardized 
number of allogeneic and autologous 
hematopoietic stem cell transplantations 
for aml patients (lower).
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Figure 8. evaluation of hematopoietic stem cell transplantation number by graft type for all patients.
Table 1. Number of patients with a first hematopoietic stem cell transplantation listed by 
disease.
Specific disease
Graft type
Total
Autologous Allogeneic
acute myelogenous leukemia   190 358 548
acute lymphoblastic leukemia   25 250 275
Other leukemia   7 7
Cml   222 222
multiple myeloma 158 3 161
plasma cell disorder 7 1 8
lymphomas 205 33 238
Solid tumors 35 6 41
Severe aplastic anemia 125 125
Thalassemia major 335 335
inherited abnormalities of RBC 29 29
auto-immune diseases 4 0 4
inherited disorder of metabolism 3 3
Disorder of immune system 13 13
Histiocytic disorders 1 1
mDS/mpS 32 32
Total 624 1418 2042
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ReSULTS
The first stem cell transplantation was performed on 31 
March 1991. From then until 31 December 2007, a tol
tal of 2042 first HSCTs have been carried out (Figure 
1). The number of HSCTs increased tenfold in the 
2000s compared to last decade. The HSCT rate during 
the past 17 years was 32.6 transplants per one million 
inhabitants and the rate per million has increased from 
1991 to 2008 (Figure 2). Of 2042 first transplantal
tions, 1418 (69%) were allogeneic and 624 (31%) were 
autologous HSCT (Figure 3). The number of allogenel
ic and autologous HSCT increased, but the allogeneic 
to autologous ratio remained constant (Figure 4). Of 
1418 allogeneic first HSCT, there were 1101 (77%) pel
ripheral blood, 281 (20%) bone marrow, 6 (0.5%) coml
bined peripheral blood and bone marrow and 16 (1.5%) 
mesenchymal with bone marrow or peripheral blood as 
stem cell sources. Of 624 autologous patients with first 
HSCT, 556 (89%) received peripheral blood, 65 (10%) 
bone marrow and 1% mixed bone marrow and periphl
eral blood as stem cell sources (Figure 5).
The donor types for 1418 allogeneic first HSCT 
were 1367 (96.4%) HLAlmatched identical siblings, 
29 (2%) HLAlmismatched siblings/other relatives, 13 
(0.9%) syngeneic twins, 5 (0.4%) HLAlmatched other 
relatives and 4 (0.3%) unrelated. The first cord blood 
HSCT was performed in 1998 and since then there 
14 patients have obtained cord blood transplantations. 
The most cord blood transplantations were in 2004. All 
of the cord blood HSCT was allogeneic and there was 
no autologous cord blood HSCT.
The main diseases for which transplant were perl
formed  are shown in 1 1.8  Allogeneic HSCT was more 
common than autologous HSCT in acute myelogenous 
leukemia and acute lymphoblastic leukemia patients. 
Patients with lymphomas, multiple myeloma, plasma 
cell disorders and solid tumors received autologous 
HSCT more frequently. On the other hand, patients 
with chronic myelogenous leukemia, severe aplastic 
anemia, hemoglobinopathies, disorders of the iml
mune system, myelodysplasia and inherited disorders 
of metabolism were treated with allogeneic HSCT. 
Autoimmune diseases were the only indication for 
only autologous HSCT. Acute myelogenous leukemia, 
thalassemia major and acute lymphoblastic leukemia 
were the most common transplanted disorders.9 Acute 
myelogenous leukemia showed a fixed increase in both 
allogeneic and autologous HSCT (Figure 6a) and the 
allogeneic to autologous ratio was stable (Figure 6b).
HSCT for thalassemia major peaked in 2001 then 
declined rapidly until 2006. Afterward, the number of 
cases increased (Figure 7). HSCT for acute lymphoblasl
tic leukemia initially started with autologous HSCT in 
1991. This was augmented by allogeneic HSCT beginl
ning in 1995, and thereafter there was an increase in all
logeneic HSCT with stable low numbers for autologous 
HSCT (Figure 8). Ninety patients received donor lyml
phocyte infusion (DLI). Some patients obtained DLI 
more than once. The total number of DLI procedures 
was 128 with the highest frequency in 2006. During 
the past 17 years, 30 patients were retransplanted. The 
common disorders in retransplanted patients were thall
assemia major, acute myelogenous leukemia, lymphol
mas and severe aplastic anemia. Cellular therapy was 
done in 111 patients, 41 patients were postlmyocardial 
infarction, 27 had cirrhosis, 20 had thalassemia major, 
11 had multiple sclerosis, 11 had head of femur necrosis 
and 1 patient had renal cell carcinoma.
DISCUSSIOn
Hematopoietic stem cell transplantation is the choice 
of treatment for many malignant, nonmalignant and 
genetic diseases. Based on a review of statistics during 
the past 17 years in HematologylOncology and Stem 
Cell Transplantation Research Center, the number and 
rate HSCT have developed considerably, especially afl
ter the year 2000. It is notable that the transplant rate 
for allogeneic HSCT was more than for autologous 
HSCT, but both have increased with a stable ratio. The 
number of HSCTs for acute myelogenous leukemia 
and acute lymphoblastic leukemia was most frequent 
amongst all disorders; the predominant type of HSCT 
for these diseases was allogeneic, which is similar to 
the EBMT (European Group for Blood and Marrow 
Transplantation) survey.10 Peripheral blood was the 
main source of HSCT as it was in the EBMT survey.11 
The most frequent donor type was allogeneic full HLAl
matched sibling. Future plans in this center include 
studies of transplants for breast cancer, neuroblastoma, 
Ewing sarcoma, soft tissue sarcoma, allogeneic HSCT 
for renal cell cancer, allogeneic HSCT for colorectal 
carcinoma and also cell therapies for postlmyocardial 
infarction, cirrhosis, thalassemia major, multiple sclerol
sis, head of femur necrosis, severe aplastic anemia and 
renal cell carcinoma.
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